Blueprint Medicines Earnings Reports

Blueprint Medicines reported strong first quarter 2025 financial results driven by significant growth in AYVAKIT/AYVAKYT net product revenues, leading the company to raise its full-year revenue guidance for AYVAKIT. The company also made progress on its pipeline with the initiation of two proof-of-concept studies for BLU-808.

Blueprint Medicines reported strong revenue growth in Q4 2024, driven by AYVAKIT sales, which more than doubled YoY. The company significantly reduced its net loss and improved operating margins.

Blueprint Medicines reported strong AYVAKIT revenue performance leading to raised full year revenue guidance to $475 million to $480 million. The company is on track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end. The company's cash position remains strong, enabling a self-sustainable financial profile.

Blueprint Medicines reported a strong second quarter, achieving $114.1 million in AYVAKIT net product revenues and raising the full-year revenue guidance to $435 million to $450 million. The company is progressing with its pipeline, including the initiation of a Phase 1 trial for BLU-808 and plans for a registration-enabling study of elenestinib.

Blueprint Medicines reported a strong first quarter with AYVAKIT net product revenues of $92.5 million, representing a 135% year-over-year growth. The company raised its full year AYVAKIT net product revenue guidance to $390 million to $410 million. Net income for the quarter was $89.1 million, driven by a one-time non-cash debt extinguishment gain.

Blueprint Medicines reported Q4 2023 revenues of $72.0 million, including $71.0 million from AYVAKIT net product revenues. The company anticipates global AYVAKIT net product revenue of approximately $360 million to $390 million in 2024.

Blueprint Medicines reported a strong third quarter, highlighted by a 90% year-over-year growth in AYVAKIT/AYVAKYT net product revenues, reaching $54.2 million, and a total revenue of $56.6 million. The company also saw a significant increase in the number of patients treated with AYVAKIT in the U.S., driven by ISM.

Blueprint Medicines reported second quarter 2023 financial results, achieving $39.9 million in AYVAKIT/AYVAKYT net product revenues and $57.6 million in total revenues. The FDA approved AYVAKIT for adults with indolent systemic mastocytosis on May 22, 2023. The company also announced development candidate BLU-808 for treating mast cell disorders.

Blueprint Medicines reported strong AYVAKIT revenue growth and progress in expanding its impact and transforming outcomes for patients. The company achieved $39.1 million in AYVAKIT/AYVAKYT net product revenues and $63.3 million in total revenues in Q1 2023. They are raising 2023 AYVAKIT net product revenue guidance to $135 million to $145 million for advanced SM and GIST.

Blueprint Medicines reported its Q4 and full year 2022 financial results, highlighting AYVAKIT's success as a standard of care for advanced systemic mastocytosis in the U.S. The company is nearing potential FDA approval of AYVAKIT for indolent SM and anticipates continued progress in clinical development programs.

Blueprint Medicines reported their Q3 2022 financial results and provided a business update, reaffirming their total revenue guidance for full-year 2022, while lowering product revenue guidance based on Q3 performance and near-term growth expectations. The company is on track to submit a supplemental new drug application for AYVAKIT in non-advanced SM in Q4 2022, with an anticipated U.S. launch in mid-2023.

Blueprint Medicines reported $36.5 million in total revenues for Q2 2022, including $28.5 million from AYVAKIT. The company is on track to announce topline data from the PIONEER trial in August and has over $1 billion in cash on its balance sheet.

Blueprint Medicines achieved $23.8 million in AYVAKIT® net product revenues and $62.7 million in total revenues. They are on track to report topline data for the registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in late summer 2022.

Blueprint Medicines reported its Q4 and full year 2021 financial results, highlighting the achievement of $53.0 million in AYVAKIT net product revenues and $180.1 million in total revenues for the full year 2021. The company anticipates significant year-over-year product revenue growth in 2022 and is expanding its research platform.

Blueprint Medicines reported third quarter 2021 financial results with strong commercial adoption of AYVAKIT and GAVRETO. The company raised its full year 2021 total revenue guidance to $170-$180 million.

Blueprint Medicines reported a revenue of $27.3 million for the second quarter of 2021, including $8.5 million from AYVAKIT/AYVAKYT and $2.9 million from GAVRETO. The company's net loss was $108.4 million, or $1.86 per share. They also initiated multiple clinical trials and announced a research collaboration with MD Anderson.

Blueprint Medicines reported total revenues of $21.6 million for the first quarter of 2021, including $7.1 million from AYVAKIT/AYVAKYT sales and $1.8 million from GAVRETO sales. The net loss for the quarter was $99.7 million, or $1.72 per share. The company's cash, cash equivalents, and investments totaled $1,430.1 million as of March 31, 2021.

Blueprint Medicines reported Q4 2020 financial results, including $6.0 million in net product revenues from AYVAKIT and $0.7 million from GAVRETO. The FDA accepted the supplemental NDA for AYVAKIT for advanced systemic mastocytosis, granting priority review with an action date of June 16, 2021.

Blueprint Medicines reported strong Q3 2020 results, highlighted by total revenues of $745.1 million, including $6.3 million from product sales, and a net income of $634.0 million. The company launched GAVRETO in the U.S. and prepared to file a supplemental NDA for AYVAKIT. Ended Q3 with approximately $1.4 billion in cash.

Blueprint Medicines reported second-quarter 2020 financial results, featuring $5.7 million in net product revenue from AYVAKIT sales and a collaboration with Roche for pralsetinib. The company is on track to report top-line data from EXPLORER and PATHFINDER trials and submit a supplemental NDA to the FDA.

Blueprint Medicines reported revenues of $6.2 million, including $3.5 million from AYVAKIT sales and $2.7 million in collaboration revenues. The company's cash, cash equivalents, and investments totaled $750.4 million as of March 31, 2020.

Blueprint Medicines reported fourth-quarter financial results with a collaboration revenue of $51.5 million. The company highlighted the FDA approval and launch of AYVAKIT, progress in pralsetinib development, and the completion of a follow-on offering, extending the cash runway into the second half of 2022.